Cargando…
Combination use of paclitaxel and avastin enhances treatment effect for the NSCLC patients with malignant pleural effusion
The current study is conducted to investigate efficacy of the chemotherapy drug paclitaxel in combination with Avastin (Roche Diagnostics GmbH., Mannheim, Germany) (antiangiogenic agent) in treatment of malignant pleural effusions (MPEs). Twenty-four patients with non–small cell lung cancer were ran...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Wolters Kluwer Health
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5134869/ https://www.ncbi.nlm.nih.gov/pubmed/27893676 http://dx.doi.org/10.1097/MD.0000000000005392 |
_version_ | 1782471539711541248 |
---|---|
author | Qi, Nan Li, Fang Li, Xiaosong Kang, Huanrong Zhao, Hui Du, Nan |
author_facet | Qi, Nan Li, Fang Li, Xiaosong Kang, Huanrong Zhao, Hui Du, Nan |
author_sort | Qi, Nan |
collection | PubMed |
description | The current study is conducted to investigate efficacy of the chemotherapy drug paclitaxel in combination with Avastin (Roche Diagnostics GmbH., Mannheim, Germany) (antiangiogenic agent) in treatment of malignant pleural effusions (MPEs). Twenty-four patients with non–small cell lung cancer were randomly assigned for 2 treatment approaches. Ten patients received paclitaxel (175 mg/m(2)) alone, and 14 patients took a combination therapy of paclitaxel and Avastin (5 mg/kg). Efficacy of the treatment approaches in the patients was validated with the change in the MPE volume. Pharmacokinetic (PK) profile and urinary excretion rate of paclitaxel were analyzed with serum vascular endothelial growth factor (VEGF) level, and adverse events were examined as well. The combination therapy reduced the MPE level with a successful rate of 29% and a survival rate of 25% over the single paclitaxel treatment in the study cohort (both P < 0.05). PKs for the combined treatment displayed a rapid distribution of the anticancer drug paclitaxel with an obvious increase in its elimination half-life in the pleural fluid (both P < 0.01). Mean residence time of paclitaxel increased in the presence of Avastin (P < 0.01). Serum VEGF levels significantly reduced in the Avastin-treated patients as compared to the paclitaxel-treated ones (P < 0.01). The urinary excretion rate was similar in the study cohort. Incidence of adverse events for the 2 treatment approaches was similar in the patients. Intervention of Avastin enhances potency of paclitaxel in treatment of MPEs with the increased survival rate of the patients through inhibiting VEGF production and prolonging time of ongoing interaction between the chemotherapy drug and the tumor tissues. |
format | Online Article Text |
id | pubmed-5134869 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2016 |
publisher | Wolters Kluwer Health |
record_format | MEDLINE/PubMed |
spelling | pubmed-51348692016-12-08 Combination use of paclitaxel and avastin enhances treatment effect for the NSCLC patients with malignant pleural effusion Qi, Nan Li, Fang Li, Xiaosong Kang, Huanrong Zhao, Hui Du, Nan Medicine (Baltimore) 5700 The current study is conducted to investigate efficacy of the chemotherapy drug paclitaxel in combination with Avastin (Roche Diagnostics GmbH., Mannheim, Germany) (antiangiogenic agent) in treatment of malignant pleural effusions (MPEs). Twenty-four patients with non–small cell lung cancer were randomly assigned for 2 treatment approaches. Ten patients received paclitaxel (175 mg/m(2)) alone, and 14 patients took a combination therapy of paclitaxel and Avastin (5 mg/kg). Efficacy of the treatment approaches in the patients was validated with the change in the MPE volume. Pharmacokinetic (PK) profile and urinary excretion rate of paclitaxel were analyzed with serum vascular endothelial growth factor (VEGF) level, and adverse events were examined as well. The combination therapy reduced the MPE level with a successful rate of 29% and a survival rate of 25% over the single paclitaxel treatment in the study cohort (both P < 0.05). PKs for the combined treatment displayed a rapid distribution of the anticancer drug paclitaxel with an obvious increase in its elimination half-life in the pleural fluid (both P < 0.01). Mean residence time of paclitaxel increased in the presence of Avastin (P < 0.01). Serum VEGF levels significantly reduced in the Avastin-treated patients as compared to the paclitaxel-treated ones (P < 0.01). The urinary excretion rate was similar in the study cohort. Incidence of adverse events for the 2 treatment approaches was similar in the patients. Intervention of Avastin enhances potency of paclitaxel in treatment of MPEs with the increased survival rate of the patients through inhibiting VEGF production and prolonging time of ongoing interaction between the chemotherapy drug and the tumor tissues. Wolters Kluwer Health 2016-11-28 /pmc/articles/PMC5134869/ /pubmed/27893676 http://dx.doi.org/10.1097/MD.0000000000005392 Text en Copyright © 2016 the Author(s). Published by Wolters Kluwer Health, Inc. All rights reserved. http://creativecommons.org/licenses/by-nc-nd/4.0 This is an open access article distributed under the terms of the Creative Commons Attribution-Non Commercial-No Derivatives License 4.0 (CCBY-NC-ND), where it is permissible to download and share the work provided it is properly cited. The work cannot be changed in any way or used commercially. http://creativecommons.org/licenses/by-nc-nd/4.0 |
spellingShingle | 5700 Qi, Nan Li, Fang Li, Xiaosong Kang, Huanrong Zhao, Hui Du, Nan Combination use of paclitaxel and avastin enhances treatment effect for the NSCLC patients with malignant pleural effusion |
title | Combination use of paclitaxel and avastin enhances treatment effect for the NSCLC patients with malignant pleural effusion |
title_full | Combination use of paclitaxel and avastin enhances treatment effect for the NSCLC patients with malignant pleural effusion |
title_fullStr | Combination use of paclitaxel and avastin enhances treatment effect for the NSCLC patients with malignant pleural effusion |
title_full_unstemmed | Combination use of paclitaxel and avastin enhances treatment effect for the NSCLC patients with malignant pleural effusion |
title_short | Combination use of paclitaxel and avastin enhances treatment effect for the NSCLC patients with malignant pleural effusion |
title_sort | combination use of paclitaxel and avastin enhances treatment effect for the nsclc patients with malignant pleural effusion |
topic | 5700 |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5134869/ https://www.ncbi.nlm.nih.gov/pubmed/27893676 http://dx.doi.org/10.1097/MD.0000000000005392 |
work_keys_str_mv | AT qinan combinationuseofpaclitaxelandavastinenhancestreatmenteffectforthensclcpatientswithmalignantpleuraleffusion AT lifang combinationuseofpaclitaxelandavastinenhancestreatmenteffectforthensclcpatientswithmalignantpleuraleffusion AT lixiaosong combinationuseofpaclitaxelandavastinenhancestreatmenteffectforthensclcpatientswithmalignantpleuraleffusion AT kanghuanrong combinationuseofpaclitaxelandavastinenhancestreatmenteffectforthensclcpatientswithmalignantpleuraleffusion AT zhaohui combinationuseofpaclitaxelandavastinenhancestreatmenteffectforthensclcpatientswithmalignantpleuraleffusion AT dunan combinationuseofpaclitaxelandavastinenhancestreatmenteffectforthensclcpatientswithmalignantpleuraleffusion |